Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 1
Submit an article Journal homepage
2,860
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

Georg Hessa Department of Hematology, Oncology and Pneumology, Comprehensive Cancer Center, University Medical School of the Johannes Gutenberg-University, Mainz, GermanyView further author information
,
Martin Dreylingb Medizinische Klinik III, LMU Klinikum, Munich, GermanyView further author information
,
Lucie Obericc Department of Hematology, University Hospital Centre Toulouse, Service d’Hématologie, Toulouse, FranceView further author information
,
Eva Gined GELTAMO, Hematology Department, Hospital Clínic of Barcelona, Barcelona, SpainView further author information
,
Pier Luigi Zinzanie IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, ItalyView further author information
,
Kim Lintonf The Manchester Cancer Research Center, Manchester, UKView further author information
,
Adam Vilmarg Odense University Hospital, Odense, DenmarkView further author information
,
Mats Jerkemanh Department of Oncology, Skane University Hospital and Lund University, Lund, SwedenView further author information
,
Jenny M. H. Cheni PRECISIONheor, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0002-0575-3699View further author information
ORCID Icon,
Anke Ohlera Department of Hematology, Oncology and Pneumology, Comprehensive Cancer Center, University Medical School of the Johannes Gutenberg-University, Mainz, GermanyView further author information
,
Stephan Stilgenbauerj Department of Internal Medicine III, Ulm University, Ulm, GermanyView further author information
,
Catherine Thieblemontk APHP, Hôpital Saint-Louis, Hemato-oncologie, Université de Paris, Paris, FranceView further author information
,
Jonathan Lambertl Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Vittorio Ruggero Ziliolim Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, ItalyView further author information
,
Juan-Manuel Sanchon GELTAMO, Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, SpainView further author information
,
Ana Jimenez-Ubietoo GELTAMO, Hospital Doce de Octubre, Madrid, SpainView further author information
,
Luca Fischerb Medizinische Klinik III, LMU Klinikum, Munich, GermanyView further author information
,
Toby A. Eyrep Haematology and Cancer Centre, Oxford, UKView further author information
,
Sam Keepingi PRECISIONheor, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0002-4281-1536View further author information
ORCID Icon,
Julie E. Parki PRECISIONheor, Vancouver, BC, CanadaView further author information
,
James J. Wuq Kite, a Gilead Company, Santa Monica, CA, USAView further author information
,
Ana Nunesq Kite, a Gilead Company, Santa Monica, CA, USAView further author information
,
John Reitanr RJM Group, LLC, Crown Point, IN, USAView further author information
,
Sally W. Wades Wade Outcomes Research & Consulting, Salt Lake City, UT, USAView further author information
&
Gilles Sallest Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
View further author information
 show all
Pages 14-25 | Received 21 Jul 2023, Accepted 02 Oct 2023, Published online: 16 Oct 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.